These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 22261118)

  • 1. Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success.
    Greenberg BM; Graves D; Remington G; Hardeman P; Mann M; Karandikar N; Stuve O; Monson N; Frohman E
    Mult Scler; 2012 Jul; 18(7):1022-6. PubMed ID: 22261118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up.
    Evangelopoulos ME; Andreadou E; Koutsis G; Koutoulidis V; Anagnostouli M; Katsika P; Evangelopoulos DS; Evdokimidis I; Kilidireas C
    J Neurol Sci; 2017 Jan; 372():92-96. PubMed ID: 28017256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab.
    Pellkofer HL; Krumbholz M; Berthele A; Hemmer B; Gerdes LA; Havla J; Bittner R; Canis M; Meinl E; Hohlfeld R; Kuempfel T
    Neurology; 2011 Apr; 76(15):1310-5. PubMed ID: 21482945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of cases of neuromyelitis optica.
    Bomprezzi R; Postevka E; Campagnolo D; Vollmer TL
    Neurologist; 2011 Mar; 17(2):98-104. PubMed ID: 21364364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder.
    Kim SH; Huh SY; Lee SJ; Joung A; Kim HJ
    JAMA Neurol; 2013 Sep; 70(9):1110-7. PubMed ID: 23897062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Individualized rituximab treatment for relapsing neuromyelitis optica: a pediatric case report.
    He D; Yu Y; Yan W; Dai Q; Xu Z; Chu L
    Pediatr Neurol; 2014 Aug; 51(2):255-8. PubMed ID: 25079575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuromyelitis optica and pregnancy during therapeutic B cell depletion: infant exposure to anti-AQP4 antibody and prevention of rebound relapses with low-dose rituximab postpartum.
    Ringelstein M; Harmel J; Distelmaier F; Ingwersen J; Menge T; Hellwig K; Kieseier B; Mayatepek E; Hartung HP; Kuempfel T; Aktas O
    Mult Scler; 2013 Oct; 19(11):1544-7. PubMed ID: 23886825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of rituximab on relapse rate and disability in neuromyelitis optica.
    Bedi GS; Brown AD; Delgado SR; Usmani N; Lam BL; Sheremata WA
    Mult Scler; 2011 Oct; 17(10):1225-30. PubMed ID: 21622594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years.
    Kim SH; Kim W; Li XF; Jung IJ; Kim HJ
    Arch Neurol; 2011 Nov; 68(11):1412-20. PubMed ID: 21747007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An open label study of the effects of rituximab in neuromyelitis optica.
    Cree BA; Lamb S; Morgan K; Chen A; Waubant E; Genain C
    Neurology; 2005 Apr; 64(7):1270-2. PubMed ID: 15824362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Individualized rituximab treatment for neuromyelitis Optica spectrum disorders.
    McKeon A; Pittock S
    JAMA Neurol; 2013 Sep; 70(9):1103-4. PubMed ID: 23896992
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical evaluation of rituximab treatment for neuromyelitis optica.
    Fernández-Megía MJ; Casanova-Estruch B; Pérez-Miralles F; Ruiz-Ramos J; Alcalá-Vicente C; Poveda-Andrés JL
    Neurologia; 2015 Oct; 30(8):461-4. PubMed ID: 25444411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of rituximab in pediatric neuromyelitis optica.
    Mahmood NA; Silver K; Onel K; Ko M; Javed A
    J Child Neurol; 2011 Feb; 26(2):244-7. PubMed ID: 21183724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica.
    Jarius S; Aboul-Enein F; Waters P; Kuenz B; Hauser A; Berger T; Lang W; Reindl M; Vincent A; Kristoferitsch W
    Brain; 2008 Nov; 131(Pt 11):3072-80. PubMed ID: 18945724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients.
    Jacob A; Weinshenker BG; Violich I; McLinskey N; Krupp L; Fox RJ; Wingerchuk DM; Boggild M; Constantinescu CS; Miller A; De Angelis T; Matiello M; Cree BA
    Arch Neurol; 2008 Nov; 65(11):1443-8. PubMed ID: 18779415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peripheral CD19
    Ellrichmann G; Bolz J; Peschke M; Duscha A; Hellwig K; Lee DH; Linker RA; Gold R; Haghikia A
    J Neurol; 2019 Jan; 266(1):57-67. PubMed ID: 30377816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case of longitudinally extensive transverse myelitis (LETM): neuromyelitis optica.
    Mangat P; Ravindran J; Cleland L; Limaye V
    Clin Rheumatol; 2008 Dec; 27 Suppl 2():S67-9. PubMed ID: 18560921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica.
    Costanzi C; Matiello M; Lucchinetti CF; Weinshenker BG; Pittock SJ; Mandrekar J; Thapa P; McKeon A
    Neurology; 2011 Aug; 77(7):659-66. PubMed ID: 21813788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolonged Remission in Neuromyelitis Optica Following Cessation of Rituximab Treatment.
    Weinfurtner K; Graves J; Ness J; Krupp L; Milazzo M; Waubant E
    J Child Neurol; 2015 Sep; 30(10):1366-70. PubMed ID: 25387545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring CD27+ memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: Results from a bicentric study.
    Cohen M; Romero G; Bas J; Ticchioni M; Rosenthal M; Lacroix R; Brunet C; Rico A; Pelletier J; Audoin B; Lebrun C
    J Neurol Sci; 2017 Feb; 373():335-338. PubMed ID: 28131216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.